CircSAMD4A aggravates H/R‐induced cardiomyocyte apoptosis and inflammatory response by sponging miR‐138‐5p

xloma.fota13 shared this article with you from Inoreader CircSAMD4A aggravates H/R‐induced cardiomyocyte apoptosis and inflammatory response by sponging miR‐138‐5p Via Journal of Cellular and Molecula... Abstract Hypoxia/reoxygenation (H/R)‐induced myocardial cell injury is the main cause of acute myocardial infarction (AMI). Many proofs show that circular RNA plays an important role in the development of AMI. The purpose of this study was to investigate the role of circSAMD4A in H/R‐induced myocardial injury. The levels of circular SAMD4A (circSAMD4A) were detected in the heart tissues of AMI mice and H/R‐induced H9C2 cells, and the circSAMD4A was suppressed in AMI mice and H/R‐induced H9C2 cells to investigate its' function in AMI. The levels of circSAMD4A and miR‐138‐5p were detected by real‐time quantitative PCR, and MTT assay was used to detect cell viability. TUNEL analysis and Annexin V‐FITC were used to determine apoptosis. The expression of Bcl‐2 and Bax proteins was detected by Western blot. IL‐1β, TNF‐α and IL‐6 were detected by ELISA kits. The study found that the levels of circSAMD4A were up‐regulated after H/R induction and inhibition of circSAMD 4A expression would reduce the H/R‐induced apoptosis and inflammation. MiR‐138‐5p was down‐regulated in H/R‐induced H9C2 cells. circSAMD4A was a targeted regulator of miR‐138‐5p. CircSAMD4A inhibited the expression of miR‐138‐5p to promote H/R‐induced myocardial cell injury in vitro and vivo. In conclusion, CircSAMD4A can sponge miR‐138‐5p to promote H/R‐induced apoptosis and inflammatory response. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Immunoexpression of BDNF, TrkB and p75NTR receptors in peripheral neural lesions of the head and neck

xloma.fota13 shared this article with you from Inoreader Immunoexpression of BDNF, TrkB and p75NTR receptors in peripheral neural lesions of the head and neck Via Oral Pathology & Medicine Abstract Background Brain‐derived neurotrophic factor (BDNF) and neurotrophin receptors have been recognized as fundamental regulators of normal brain development, homeostasis and plasticity. They have also been studied in the behavior of central nervous system tumors. Here we studied the pattern of BDNF, TrkB and p75NTR immunoexpression in peripheral benign and malignant neural lesions in head and neck. Methods This cross‐sectional analytical study included 79 cases of head and neck neural lesions. Nineteen cases of traumatic neuromas (TN), 20 cases of granular cell tumors (GCT), 16 cases of neurofibromas (NF), 20 cases of schwannomas (SC) and 4 malignant peripheral nerve sheath tumour (MPNST) were submitted to immunohistochemistry with BDNF, TrkB and p75NTR antibodies. A semi‐quantitative analysis was performed. Results The analysis of BDNF demonstrated a high percentage of positive cells in TN, GCT and SC with a decrease in cases of NF and MPNST. TrkB presented a lower significant immunoexpression in GCT in relation to the TN, NF, SC and MPNST (p < 0.0001); and TN showed less percentage of positive cell compared to SC (p = 0.0017). Regarding p75NTR, the percentage of positive cell was significantly reduced in MPNST compared GCT (p = 0.009), NF (p = 0.0138) and SC (p = 0.0069). Also, a decrease in TN compared to GCT (p = 0.007) were observed. Conclusions Our results showed the immunoreactivity of BDNF, TrkB and p75NTR in head and neck peripheral neural lesions. Reduction of BDNF and p75NTR in MPNST might suggest downregulation during the acquisition of malignant phenotype. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

RhoA/ROCKs signalling is increased by treatment with TKI‐258 and leads to increased apoptosis in of SCC‐4 oral squamous cell carcinoma cell line

xloma.fota13 shared this article with you from Inoreader RhoA/ROCKs signalling is increased by treatment with TKI‐258 and leads to increased apoptosis in of SCC‐4 oral squamous cell carcinoma cell line Via Oral Pathology & Medicine Abstract Background This study evaluated the effect of treatment with TKI‐258 on apoptosis, involving Rho GTPases and their effectors in SCC‐4 cells of oral squamous cell carcinoma. Methods Markers of cell death and apoptosis were analyzed in control and TKI‐258 treated SCC‐4 cells by flow cytometry. The involvement of Rho GTPases and effectors in the induction of apoptosis by TKI‐258 was evaluated by quantification of cleaved PARP. Also gene expression analysis of those proteins was performed. Results The treatment with TKI‐258 led to a significant increase in cell death (7‐AAD) and apoptosis (Annexin V and cleaved PARP). When Rho GTPases were stimulated with LPA and inhibited with Toxin A Clostridium difficile, the percentage of apoptotic cells increased and decreased, respectively. A similar effect was found when the treatment was with TKI‐258 combined with LPA and Toxin A. Treatment with TKI‐258 significantly increased RhoA gene expression, while RhoB, RhoC, Rac1 and Cdc42 decreased significantly. ROCKs inhibitors (Y‐27632 and HA‐1077) reduced apoptosis compared with control. TKI‐258 combined with Y‐27632 or HA‐1077 led to an increase in apoptosis compared with inhibitors only. Treatment with TKI‐258 led to an increase in ROCK1 and ROCK2 gene expression, and a decrease in PAK1 and PAK2 gene expression. Conclusions TKI‐258 stimulates apoptosis in SCC‐4 cells of oral squamous cell carcinoma. Possibly, RhoA GTPase and their effectors ROCKs participate in the signalling pathway inhibited by TKI‐258. Clinical Relevance: Therapies with multi‐target inhibitors, such as TKI‐258, may be promising alternatives for the clinical treatment of oral squamous cell carcinoma. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

miRNA for the assessment of lymph node metastasis in patients with oral squamous cell carcinoma: systematic review and metanalysis

xloma.fota13 shared this article with you from Inoreader miRNA for the assessment of lymph node metastasis in patients with oral squamous cell carcinoma: systematic review and metanalysis Via Oral Pathology & Medicine Abstract Background MiRNA is one of the advanced epigenetic molecular markers correlating with lymph node metastasis in patients with OSCC. Numerous published papers are showing correlation of miRNA with metastasis. There is a need to analyze and validate such correlation Method English language literature in major databases from the last 20 years was searched using controlled vocabulary and keywords. Strict inclusion and exclusion criterias were followed for selection of studies. The quality assessment was done as per the QUADAS tool 2 by three independent reviewers. The metanalysis was performed by using random effect model. Standardized Mean Difference (SMD) was considered as the effect measure. Statistical software used was STATA version 13.1. Results With all inclusion and exclusion criteria, eight studies could qualify for metanalysis. The pooled estimate is found to be 0.13 (‐0.35, 0.62), P=0.585, which is statistically not significant. This indicates that there is a no significant difference in the fold change between metastasis and no metastasis groups. P‐value of Chi‐square statistic for heterogeneity is <0.001 (significant) and I‐squared statistic is 87.2%, which indicates that heterogeneity is present to a considerable extent. Egger's test shows there is no publication bias involved (P=0.819). Conclusion The metanalysis showed no significant difference in the fold change of miRNA expression between metastasis and non metastasis OSCC patients. Future studies can be directed to eliminate the heterogeneity among the studies noted in this analysis to confirm the role of miRNA for assessment of regional metastasis with special focus on tongue squamous cell carcinoma. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

High expression of novel biomarker KRT16P3 promotes the progression of tongue squamous cell carcinoma and predicts poor prognosis

xloma.fota13 shared this article with you from Inoreader High expression of novel biomarker KRT16P3 promotes the progression of tongue squamous cell carcinoma and predicts poor prognosis Via Oral Pathology & Medicine Abstract Background Overexpression of long noncoding RNAs (lncRNAs) reveals the abnormal pathological processes in many human cancers. KRT16P3, a novel overexpressed lncRNA in tongue squamous cell carcinoma (TSCC), was identified by previous lncRNA microarrays. However, the role of KRT16P3 in TSCC is not clear. Methods Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to detect the expression of KRT16P3 in TSCC tissues and cells. Next, the relationships between KRT16P3 and the clinical significance of TSCC patients were analyzed. Additionally, Cell Counting Kit‐8, 5‐Bromo‐2‐deoxyUridine (BrdU) incorporation assay, cell colony formation assay, flow cytometry cell apoptosis analysis, scratch wound healing assay, transwell invasion assay were used to explore the biological function of KRT16P3. Western blot and qRT‐PCR were used to determine the expression of epithelial‐mesenchymal transition (EMT) markers. The pathway changes after KRT16P3 knockdown were detected by western blot. Results We found KRT16P3 expression is significantly upregulated in TSCC tissues and positively associated with advanced clinicopathological features of TSCC patients, and it may serve as a poor prognostic factor. Functionally, KRT16P3 knockdown inhibits proliferation, migration, invasion, and promotes apoptosis of TSCC cells. Furthermore, we also revealed that KRT16P3 knockdown supresses EMT and JAK2/STAT3 signaling pathway. Conclusion Our results validated that KRT16P3 can modulate the malignant progression, EMT process, and JAK2/STAT3 signaling pathway of TSCC, which might also serve as a novel prognostic biomarker and an attractive target for TSCC patients. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: a randomised controlled clinical trial and monitoring blood concentration

xloma.fota13 shared this article with you from Inoreader Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: a randomised controlled clinical trial and monitoring blood concentration Via Oral Pathology & Medicine Abstract Background Tacrolimus has been used to treat various inflammatory skin diseases, but its safety for topical application on the oral mucosa is unknown. Exfoliative cheilitis (EC) is a chronic inflammatory disorder of the lips characterised by repeated scaling; it is difficult to manage. The aim of this study was to assess the efficacy and safety of tacrolimus 0.03% ointment as a topical treatment in patients with EC. Methods In this randomised controlled clinical trial, 40 patients with EC were randomly assigned to receive either tacrolimus 0.03% ointment (experimental group, n = 20) or triamcinolone acetonide 0.1% cream (control group, n = 20) treatment for a 3‐week period. Medication was administered in 3, 2, and 1 daily doses during the first, second, and third weeks, respectively. The patients with complete healing were followed up for 3 months. The clinical outcomes were measured, including the scores regarding signs (scale, dryness, rhagades, and swelling) and symptoms (rough, dry, pain, pruritus, and burning sensation) at every visit. Blood concentrations of tacrolimus were assessed. Results After the 3‐week treatment, healing rates of scale in the experimental and control groups were 65% and 10%, respectively (P = 0.018). Improvement in all signs and two symptoms (rough, pruritus) was much greater in the experimental group (P < 0.05). The 3‐month recurrence rate was higher in the control group (P = 0.029). Tacrolimus blood concentrations were in the safe range (< 5 ng/mL). Conclusion Topical tacrolimus 0.03% ointment has good short‐term efficacy and safety for treating EC. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Elective neck dissection in primary parotid carcinomas: a systematic review and meta‐analysis

xloma.fota13 shared this article with you from Inoreader Elective neck dissection in primary parotid carcinomas: a systematic review and meta‐analysis Via Oral Pathology & Medicine Abstract Background To estimate the rate of occult cervical lymph node metastases in cN0 patients affected by primary parotid carcinomas and to scrutinize the evidence on the indication and extent of elective neck dissection in these neoplasms. Methods Medline, Embase, Web of Science, Cochrane Library and Scopus were searched until August 31, 2020, to identify studies reporting the use of elective neck dissection in the management of malignant parotid tumours. The PRISMA checklist was used. A single arm meta‐analysis was then made to determine the pooled rate of occult lymph node metastases. Risk of bias of the included studies was assessed through the ROBINS‐E tool. Results The initial search returned 20541 articles, of which twelve met the inclusion criteria and were included in the meta‐analysis. They comprised 1310 patients with parotid carcinoma, of whom 542 cN0 underwent elective neck dissection, which led to the diagnosis of lymph node metastasis (pN+/cN0) in 113 cases. Meta‐analysis of the results of elective neck dissection showed an overall rate of occult metastases of 0.22 (99% CI: 0.14‐0.30). Locally advanced or high‐grade tumors were the commonest indications for elective neck dissection in the included studies. The most dissected lymph node levels were I‐II‐III, and level II was the commonest site of occult nodal metastases. Conclusions An occult metastasis rate of 0.22 (99% CI: 0.14‐0.30) represents a not negligible percentage value, which should encourage further research to outline the most appropriate elective neck management in cN0 patients with parotid carcinomas. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.